Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
CRVO
#4451
CervoMed Inc. Common Stock
4.0
4
USD
+0.75%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+0.75%
Changement Mensuel
-5.39%
Evolution sur 6 mois
-50.79%
Changement Annuel
-60.78%
Clôture Précédente
4.0
1
Open
4.0
4
Bid
Ask
Low
4.0
4
High
4.0
4
Volume
4
Marchés
Actions des Marchés US
Soins de Santé
CRVO
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
2.04 M
2.04 M
2.04 M
6.17 M
8.7 M
9.26 M
—
Valuation ratios
Enterprise value
—
—
—
41.57 M
11.36 M
64.91 M
249.29 M
Price to earnings ratio
—
—
—
-9.8
-1.16
-2.65
-11.93
Price to sales ratio
—
—
—
2.98
1.94
17.83
44.4
Price to cash flow ratio
—
—
—
-2.86
-1.14
-3.05
-12.22
Price to book ratio
—
—
—
2.89
0.48
3.92
5.34
Enterprise value to EBITDA ratio
—
—
—
—
—
-2.23
—
Profitability ratios
Return on assets %
-0.51
-0.64
-0.69
-0.22
-0.38
-1.18
-0.9
Return on equity %
-0.57
-0.69
-0.77
-0.29
-0.42
-1.48
-1.07
Return on invested capital %
-644.96
-2 666.82
11.49 K
-211.81 K
-1.36 M
13.85 K
—
Gross margin %
—
100
—
100
100
100
400
Operating margin %
—
47.66 K
—
-109.35
-187.18
-706.22
-98.63 K
EBITDA margin %
—
31.26 K
—
—
—
-727.54
—
Net margin %
—
46.53 K
—
-30.4
-167.29
-673.06
-95.69 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
7.71
12.92
7.3
2.46
8.66
4.91
24.16
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
-0
0
0.44
0.37
0.12
0.1
Solvency ratios
Debt to assets ratio
—
—
—
0
—
—
—
Debt to equity ratio
—
—
—
0
—
—
—
Long term debt to total assets ratio
—
—
—
0
—
—
—
Long term debt to total equity ratio
—
—
—
0
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
-2.8
-2.05
-2.59
-2.6
EBIT per share
—
—
—
-2.94
-2.26
-3.13
-3.14
EBITDA per share
—
—
—
—
—
-3.22
—
Total debt per share
—
—
—
0
—
—
—
Cash per share
—
—
—
2.93
4.82
2.31
13.05
Net current asset value per share
—
—
—
3.74
5.34
2.53
14.53
Tangible book value per share
—
—
—
2.77
4.86
2.02
12.54
Working capital per share
—
—
—
2.22
4.72
2.02
12.11
Book value per share
—
—
—
2.77
4.86
2.02
12.54
Nouvelles
CervoMed présente les données de phase 2b pour le neflamapimod
H.C. Wainwright réitère sa recommandation sur CervoMed suite aux données de conférence
H.C. Wainwright reiterates CervoMed stock rating on conference data
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street - TipRanks.com
CervoMed fixe la dose de 50 mg pour l’essai de phase 3 sur la démence
CervoMed sets 50mg dose for phase 3 dementia trial
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?
Le neflamapimod de CervoMed sélectionné pour un essai britannique sur la SLA
CervoMed’s neflamapimod selected for UK ALS trial platform
Cantor Fitzgerald initie la couverture de CervoMed avec une note Surpondérer
Cantor Fitzgerald initiates CervoMed stock with Overweight rating